Literature DB >> 3120782

Rhizoxin binding to tubulin at the maytansine-binding site.

M Takahashi1, S Iwasaki, H Kobayashi, S Okuda, T Murai, Y Sato.   

Abstract

The binding of rhizoxin, a potent inhibitor of mitosis and in vitro microtubule assembly, to porcine brain tubulin was studied. Tubulin possesses one binding site for rhizoxin per molecule with a dissociation constant (Kd) of 1.7.10(-7) M. Ansamitocin P-3, a homologue of maytansine, was a competitive inhibitor of rhizoxin binding, with an inhibition constant of 1.3.10(-7) M. Vinblastine also inhibited rhizoxin binding, but was not fully competitive, and the inhibition constant was 2.9.10(-6) M. In contrast, both rhizoxin and ansamitocin P-3 were potent inhibitors of vinblastine binding. Rhizoxin inhibited tau-promoted tubulin assembly, but it, differing from vinblastine, did not induce tubulin aggregation into spirals, even at a concentration as high as 2.10(-5) M. In addition, rhizoxin strongly inhibited vinblastine-induced tau-dependent tubulin aggregation. Rhizoxin binding to tubulin was completely independent from colchicine binding. These effects resemble those of maytansine. The results suggested that rhizoxin binds to the maytansine-binding site and that the binding sites of rhizoxin and vinblastine are not the same.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120782     DOI: 10.1016/0304-4165(87)90206-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

2.  Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice.

Authors:  A Kurihara; Y Shibayama; A Mizota; A Yasuno; M Ikeda; K Sasagawa; T Kobayashi; M Hisaoka
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

3.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.

Authors:  Andrea E Prota; Katja Bargsten; J Fernando Diaz; May Marsh; Carmen Cuevas; Marc Liniger; Christian Neuhaus; Jose M Andreu; Karl-Heinz Altmann; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

5.  A previously undescribed tubulin binder.

Authors:  Jessica J Field; Andrew B Waight; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-03       Impact factor: 11.205

6.  Burkholderia as a Source of Natural Products.

Authors:  Sylvia Kunakom; Alessandra S Eustáquio
Journal:  J Nat Prod       Date:  2019-07-11       Impact factor: 4.050

7.  Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

Authors:  T Tokui; N Maeda; C Kuroiwa; K Sasagawa; T Inoue; K Kawai; T Ikeda; T Komai
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

8.  Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway.

Authors:  T Tokui; T Takatori; N Shinozaki; M Ishigami; A Shiraishi; T Ikeda; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans.

Authors:  M Takahashi; H Kobayashi; S Iwasaki
Journal:  Mol Gen Genet       Date:  1989-12

10.  Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

Authors:  Walid Fayad; Mårten Fryknäs; Slavica Brnjic; Maria Hägg Olofsson; Rolf Larsson; Stig Linder
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.